Synairgen SNG001

Trial summary: a randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection

Type: Interventional

Site and lead:

  • Wythenshawe Hospital, Dr Tim Felton

Patient group: All COVID-19 patients

Funder: Synairgen Research Limited

Sponsor: Synairgen Research Limited

More about the Synairgen SNG001 study

The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of lower respiratory tract (LRT) illness in the context of SARS-CoV-2. Safety and efficacy will be assessed.

SNG001 is an inhaled formulation of interferon-beta-1a (IFN-β1a), a respiratory drug which has been found to inhibit viruses and boost antiviral responses in the lungs. It has already been used in clinical trials of patients with asthma and COPD. These earlier trials indicated that SNG001 was well tolerated during virus infections and provided significant lung function benefit for asthma patients, compared to a placebo.